



Final Appraisal Recommendation

Advice No: 0415 – March 2015

**Dolutegravir/abacavir/lamivudine (Triumeq[®]▼)
50 mg/600 mg/300 mg film-coated tablets**

Limited submission by ViiV Healthcare UK Ltd

Recommendation of AWMSG

Dolutegravir/abacavir/lamivudine (Triumeq[®]▼) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2365), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	ViiV Healthcare UK Ltd
Date of first issue	March 2015
Last reviewed	March 2018

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0415:
Dolutegravir/abacavir/lamivudine (Triumeq[®]▼) 50 mg/600 mg/300 mg film-coated tablets.
March 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.